$29.32
0.54% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$29.32
+4.42 17.75% 1M
+7.86 36.63% 6M
+7.74 35.87% YTD
+10.24 53.67% 1Y
-47.47 61.82% 3Y
+3.91 15.39% 5Y
+7.92 37.01% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.16 0.54%
ISIN
US14843C1053
Symbol
CSTL
Sector

Key metrics

Market capitalization $813.24m
Enterprise Value $578.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 22.59
EV/Sales (TTM) EV/Sales 2.01
P/S ratio (TTM) P/S ratio 2.83
P/B ratio (TTM) P/B ratio 1.92
Revenue growth (TTM) Revenue growth 71.67%
Revenue (TTM) Revenue $287.59m
EBIT (operating result TTM) EBIT $-15.76m
Free Cash Flow (TTM) Free Cash Flow $25.62m
Cash position $259.69m
EPS (TTM) EPS $-0.13
P/E forward negative
P/S forward 2.74
EV/Sales forward 1.95
Short interest 6.33%
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

Buy
100%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
288 288
72% 72%
100%
- Direct Costs 63 63
26% 26%
22%
225 225
91% 91%
78%
- Selling and Administrative Expenses 174 174
13% 13%
61%
- Research and Development Expense 53 53
7% 7%
19%
-2.67 -2.67
97% 97%
-1%
- Depreciation and Amortization 13 13
12% 12%
5%
EBIT (Operating Income) EBIT -16 -16
84% 84%
-5%
Net Profit -3.10 -3.10
97% 97%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
Seeking Alpha
23 days ago
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
Neutral
Seeking Alpha
about one month ago
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genui...
Neutral
Business Wire
about one month ago
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 610
Founded 2007
Website www.castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today